0N70.L - Biotest Aktiengesellschaft

LSE - LSE Prezzo differito. Valuta in EUR.

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 6103 801 0
http://www.biotest.com

Settore
Settore
Impiegati a tempo pieno1.837

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Michael RamrothChairman of the Management Board, CEO & CFO1,11MN/D1961
Dr. Georg FloßCOO & Member of the Board of Management882kN/DN/D
Dr. Monika ButtkereitHead of Investor RelationsN/DN/DN/D
Dr. Christina ErbHead of Corp. HRN/DN/DN/D
Dr. Katrin BernösterHead of the Project Management OrganisationN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; Zutectra for hepatitis B re-infection prophylaxis after liver transplantation; and Cytotect 70(BT-094) for prevention of cytomegalovirus infection in the foetus during pregnancy with mother's CMV infection. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.

Governance aziendale

L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.
Usando Yahoo accetti che Yahoo e i suoi partners utilizzino cookies per fini di personalizzazione e altre finalità